Screening for Memory Studies | Clinical Trial

Key information

Conditions

Memory Loss Alzheimer Disease Brain Diseases Central Nervous System Diseases Dementia Memory Deficits Memory Disorders Mental Disorders Nervous System Diseases Neurobehavioral Manifestations Neurocognitive Disorders Neurodegenerative Diseases Neurologic Manifestations Pathological Conditions, Signs and Symptoms Signs and Symptoms Tauopathies

Age range

21 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

VA Palo Alto Health Care System

Palo Alto, California, 94304, United States

About this study

The purpose of this protocol is to advertise, recruit, and do a preliminary screen for various clinical trials. Anonymous information collected will be entered in a database available to researchers connected with the Stanford/VA Aging Clinical Research Center, located at VA Palo Alto Health Care System, Palo Alto Division.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age 21 or over.

Exclusion criteria

Major psychiatric problems.
Major medical problems.
Aversion to test-taking.

Treatment and study plan

Memtrax Memory screening test

Behavioral

Memory Screening test

Other names: Memory screening

Primary outcomes

Memory Impairment

Time frame: 90 seconds to 150 seconds (normal less than 100 seconds)

The primary outcome measure on a 50 item Continuous Recognition Task with 25 repeated items, first display of an item is 3 seconds, new image immediately after a response (MemTrax, see: reference), is number of HITs (a memory measure). Less than 20 suggests memory impairment and will trigger referral to a memory study.

Secondary outcomes

Processing speed measurement with MemTrax

Time frame: 90 - 150 seconds (normal - 95 seconds)

Secondary outcome measure is response time to HITs (a measure of memory processing speed), usually 0.550 to 1.5 seconds. Slower than 1.2 seconds suggests a memory, attention, or processing speed problem, will also trigger a referral to the memory study. Note, a third measure, number of Correct Rejections (a measure of executive function), is used to validate the first and second outcome measures. Values below 20 suggest that the other measures might not be valid.

Sponsors and collaborators

Lead sponsor

John Wesson Ashford Jr

Fed

Registry information

Important dates

Study start: 2007
Primary completion: 2023
Study completion: 2023
First posted: May 13, 2010
Registry last updated: Aug 26, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed